Cannabis Policy
Medical Cannabis Users Could Still be Criminalised in UK Despite Government Accepting its Benefits
Under current recommendations, people who use cannabis for conditions including chronic pain, arthritis, the side effects of chemotherapy and even the self-medication of brain and other tumours, will continue to be criminalised.
Torts and Courts: How the Cannabis Industry Can Protect Itself from Legal Action
The cannabis industry has largely escaped negligence cases to date, mainly due to legal uncertainties - experts claim this ‘tort cease-fire’ is coming to an end.
Crime Clearance Rates Positively Impacted by Cannabis Legalization
In Colorado and Washington arrest rates for cannabis has fallen and crime clearance rates for violent crime, burglary, motor vehicle theft and property crime have shifted upward.
Multiple Case Studies Show Potential Danger of Cannabis Contaminants
Preventive steps and remediative action are required to reduce the prevalence of contamination from microbes, heavy metals and, pesticides.
CBD Market Set to Grow as Regulatory Change Looms in U.S.
The market for cannabis and hemp products has seen a low-key but potentially huge step forward in recent weeks.
A Big Step Forward for Medical Marijuana
Medical marijuana has picked up considerable momentum after a U.S. FDA advisory panel unanimously recommended approval of GW Pharmaceuticals' epilepsy medication, Epidolex.
Medical Cannabis and the Challenge for Regulation of Medicines
Reviews of scientific evidence show promising findings for some, but not all, conditions for which cannabis is considered a treatment – and this evidence is difficult to untangle.
Advancing Cannabinoid Research in Australia
Pioneering researchers are developing cannabinoid formulations to help doctors and patients control their dosing, as well as help researchers better study the drug in clinical trials.
Monopoly on FDA-approved Cannabis May Hold Back Parkinson's Drug Development
GB Sciences are looking for international suppliers that produce minor cannabinoids and terpenes to ensure that it can expand testing beyond their planned, initial Phase 0 Trial.
